|
|
1. Vaccine Search:
Found 636 vaccine(s) whose description contains the queried keyword(s). Please click a vaccine name for detail. To compare vaccines, check two or more vaccines and click "Compare".
2. Pathogen Search:
Found
13 pathogen(s) related to the query keywords:
3. Vaccine-related Gene Search:
Found 13 vaccine-related gene(s).
NOTE: Go to Vaxgen for advanced vaccine gene search.
4. Vaccine-related Literature:
Found 1117 vaccine-related article(s).
-
Pifferi C, Goyard D, Aguinagalde L, Renaudet O, Anguita J, Fernández-Tejada A Design, synthesis and immunological evaluation of CRM(197)-based immunogens functionalized with synthetic scaffolds displaying a tumor-associated MUC1 glycopeptide.. Biomaterials science. 2026; 14(1); 256-263. [PubMed: 41263603].
-
He Y, Zhou B, Tong J, Ji Z, Wang N, Lai H, Wang J, Zhu C, Mai X, Xu C, Wang PG, Zhou D Immunogenicity of mRNA encoded MUC1 glycopeptides toward CAR-T cells.. European journal of cell biology. 2026; 105(3); 151543. [PubMed: 42143891].
-
Fuentes R, Tonon-Baschirotto P, Aguinagalde L, Fernández-Tejada A Synthesis and In Vivo Immunological Evaluation of Novel Saponin-Antigen Conjugates Incorporating Tumor-Associated Carbohydrate and Peptide Epitopes.. Chemistry (Weinheim an der Bergstrasse, Germany). 2026; ; e71192. [PubMed: 42210026].
-
Zhang R, Sun Y, Ding F, Ju W, Chu Z, Ren Z, He Z, Wang X, Wang P Antitumor Immunity Mediated by Nanoreactors Based on Bacterial Membrane Vesicles.. Molecular pharmaceutics. 2026; ; . [PubMed: 42228764].
-
Wu Y, Ma W, Jiang Y, Ling Y, Zhou Y, Guo Y, Hong S, Ding F, Zhang J, Li B, Liang H, Wang Z, Li Y, Li T, Cai H A Glycopeptide Mosaic Vaccine Elicits Robust Antitumor Immunity by Targeting Glycan Heterogeneity.. JACS Au. 2026; 6(1); 469-482. [PubMed: 41614196].
-
Monfaredan A, Şen S, Fathi NK, Taştekin D, Hosseininasab A, Bozbey HU, Öncül O Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model.. International journal of molecular sciences. 2025; 26(17); . [PubMed: 40943370].
-
Teng C, Ma W, Liu J, Hou J, Zhang Y, Meng X, Xue Y, Wang Z, Wang J, Chen D, Sui Q, Gao Q, Li X, Li T, Zong C Chemoenzymatic liquid-phase synthesis and immunogenic assessment of tumor-associated complex MUC1 glycopeptide variants.. International journal of biological macromolecules. 2025; 302; 140525. [PubMed: 39892541].
-
Ghirardello M, Guerreiro A, Bretón C, Compañón I, Zabalza J, Mangini V, Peregrina JM, Bernardes GJL, Corzana F Balancing Antigen Loading on Gold Nanoparticles: Implications for Future Cancer Vaccine Strategies.. Chemistry (Weinheim an der Bergstrasse, Germany). 2025; 31(38); e202501286. [PubMed: 40448390].
-
Gibadullin R, Suárez Ó, Lazaris FS, Gutiez N, Atondo E, Araujo-Aris S, Eguskiza A, Niu J, Kuhn AJ, Grosso AS, Rodriguez H, García-Martín F, Marcelo F, Santos T, Avenoza A, Busto JH, Peregrina JM, Gellman SH, Anguita J, Fiammengo R, Corzana F Enhancing Cancer Vaccine Efficacy: Backbone Modification with β‑Amino Acids Alters the Stability and Immunogenicity of MUC1-Derived Glycopeptide Formulations.. JACS Au. 2025; 5(5); 2270-2284. [PubMed: 40443897].
-
Xie H, Yang W, Chen H, Zhang Z, Zhao Z, Jin Y, Fan S, Yang Z MUC1 peptide-loaded dendritic cell vaccine boosts antitumor immunity in pancreatic cancer.. Frontiers in immunology. 2025; 16; 1752861. [PubMed: 41607777].
-
Pennathur A, Midthun D, Wojtowicz M, Ward J, Forster J, Krpata T, Fatis S, McKolanis J, Xue J, Beatty P, Kaufman S, Akerley C, Felt A, Fursa K, Holland A, Ambulay L, Foster NR, Strand C, Salazar A, Bengtson L, Szabo E, Limburg P, Finn OJ A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer.. medRxiv : the preprint server for health sciences. 2025; ; . [PubMed: 40666355].
-
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer [https://clinicaltrials.gov/study/NCT03300817]
-
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer [https://clinicaltrials.gov/study/NCT05098210]
-
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery [https://clinicaltrials.gov/study/NCT05111353]
-
SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) [https://clinicaltrials.gov/study/NCT04079166]
-
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC [https://clinicaltrials.gov/study/NCT04912765]
-
Bermejo IA, Guerreiro A, Eguskiza A, Martínez-Sáez N, Lazaris FS, Asín A, Somovilla VJ, Compañón I, Raju TK, Tadic S, Garrido P, García-Sanmartín J, Mangini V, Grosso AS, Marcelo F, Avenoza A, Busto JH, García-Martín F, Hurtado-Guerrero R, Peregrina JM, Bernardes GJL, Martínez A, Fiammengo R, Corzana F Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses.. JACS Au. 2024; 4(1); 150-163. [PubMed: 38274250].
-
Du JJ, Zhou SH, Liu J, Zhong XY, Zhang RY, Zhao WX, Wen Y, Su ZH, Lu Z, Guo J Diphtheria Toxoid-Derived T-Helper Epitope and α-galactosylceramide Synergistically Enhance the Immunogenicity of Glycopeptide Antigen.. ACS pharmacology & translational science. 2024; 7(12); 3889-3901. [PubMed: 39698257].
-
Guerreiro A, Compañón I, Lazaris FS, Labão-Almeida C, Oroz P, Ghirardello M, Marques MC, Corzana F, Bernardes GJL Non-Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity.. Angewandte Chemie (International ed. in English). 2024; 63(49); e202411009. [PubMed: 39275921].
-
Liang C, Geng L, Dong Y, Zhang H VEGF165b mutant can be used as a protein carrier to form a chimeric tumor vaccine with Mucin1 peptide to elicit an anti-tumor response.. Molecular immunology. 2024; 175; 31-39. [PubMed: 39298996].
-
Cameron CM, Raghu V, Richardson B, Zagore LL, Tamilselvan B, Golden J, Cartwright M, Schoen RE, Finn OJ, Benos PV, Cameron MJ Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention.. Frontiers in immunology. 2024; 15; 1437391. [PubMed: 39450169].
-
McKeague ML, Lohmueller J, Dracz MT, Saadallah N, Ricci ED, Beckwith DM, Ayyalasomayajula R, Cudic M, Finn OJ Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.. Antibodies (Basel, Switzerland). 2024; 13(4); . [PubMed: 39449327].
-
Guo Q, Wang L, Wuriqimuge, Dong L, Feng M, Bao X, Zhang K, Cai Z, Qu X, Zhang S, Wu J, Wu H, Wang C, Yu X, Kong W, Zhang H Metformin improved a heterologous prime-boost of dual-targeting cancer vaccines to inhibit tumor growth in a melanoma mouse model.. International immunopharmacology. 2024; 128; 111431. [PubMed: 38244520].
-
Wu Y, Zhou Y, Guo Y, Ling Y, Li Y, Cai H Protocol to prepare MUC1 glycopeptide vaccines and evaluate immunization effects in mice.. STAR protocols. 2024; 5(2); 103047. [PubMed: 38691463].
-
Dendritic Cell Vaccination in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT03092453]
-
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (DEMAND) [https://clinicaltrials.gov/study/NCT04741984]
-
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery [https://clinicaltrials.gov/study/NCT04197687]
-
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) [https://clinicaltrials.gov/study/NCT04574583]
-
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer [https://clinicaltrials.gov/study/NCT00017537]
-
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) [https://clinicaltrials.gov/study/NCT02728102]
-
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) [https://clinicaltrials.gov/study/NCT05533203]
-
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) [https://clinicaltrials.gov/study/NCT05638698]
-
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection [https://clinicaltrials.gov/study/NCT04247282]
-
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO) [https://clinicaltrials.gov/study/NCT03396575]
-
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma [https://clinicaltrials.gov/study/NCT01081223]
-
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission [https://clinicaltrials.gov/study/NCT03059485]
-
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission [https://clinicaltrials.gov/study/NCT01096602]
-
Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, Cheong TC, Leonardi G, Karaca-Atabay E, Campisi M, Poggio T, Menotti M, Ambrogio C, Longo DL, Klaeger S, Keshishian H, Sztupinszki ZM, Szallasi Z, Keskin DB, Duke-Cohan JS, Reinhold B, Carr SA, Wu CJ, Moynihan KD, Irvine DJ, Barbie DA, Reinherz EL, Voena C, Awad MM, Blasco RB, Chiarle R ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.. Nature cancer. 2023; 4(7); 1016-1035. [PubMed: 37430060].
-
Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes [https://clinicaltrials.gov/study/NCT00361296]
-
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT05359354]
-
Oji Y, Kagawa N, Arita H, Naka N, Hamada KI, Outani H, Shintani Y, Takeda Y, Morii E, Shimazu K, Suzuki M, Nishida S, Nakata J, Tsuboi A, Iwai M, Hayashi S, Imanishi R, Ikejima S, Kanegae M, Iwamoto M, Ikeda M, Yagi K, Shimokado H, Nakajima H, Hasegawa K, Morimoto S, Fujiki F, Nagahara A, Tanemura A, Ueda Y, Mizushima T, Ohmi M, Ishida T, Fujimoto M, Nonomura N, Kimura T, Inohara H, Okada S, Kishima H, Hosen N, Kumanogoh A, Oka Y, Sugiyama H WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.. Cancers. 2023; 15(2); . [PubMed: 36672344].
-
Gabba A, Attariya R, Behren S, Pett C, van der Horst JC, Yurugi H, Yu J, Urschbach M, Sabin J, Birrane G, Schmitt E, van Vliet SJ, Besenius P, Westerlind U, Murphy PV MUC1 Glycopeptide Vaccine Modified with a GalNAc Glycocluster Targets the Macrophage Galactose C-type Lectin on Dendritic Cells to Elicit an Improved Humoral Response.. Journal of the American Chemical Society. 2023; 145(24); 13027-13037. [PubMed: 37279388].
-
Pifferi C, Aguinagalde L, Ruiz-de-Angulo A, Sacristán N, Baschirotto PT, Poveda A, Jiménez-Barbero J, Anguita J, Fernández-Tejada A Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen.. Chemical science. 2023; 14(13); 3501-3513. [PubMed: 37006677].
-
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, Pai RK, Singhi AD, Jacqueline CM, Bao R, Diergaarde B, McMurray RP, Strand C, Foster NR, Zahrieh DM, Limburg PJ, Finn OJ Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023; 29(9); 1678-1688. [PubMed: 36892581].
-
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma [https://clinicaltrials.gov/study/NCT00911560]
-
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer [https://clinicaltrials.gov/study/NCT04348747]
-
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma [https://clinicaltrials.gov/study/NCT00101101]
-
Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant [https://clinicaltrials.gov/study/NCT05457959]
-
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer [https://clinicaltrials.gov/study/NCT04270149]
-
Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022; 28(4); 689-696. [PubMed: 34862245].
-
Ju M, Fan J, Zou Y, Yu M, Jiang L, Wei Q, Bi J, Hu B, Guan Q, Song X, Dong M, Wang L, Yu L, Wang Y, Kang H, Xin W, Zhao L Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer.. Frontiers in immunology. 2022; 13; 807840. [PubMed: 35812443].
-
Chung DJ, Sharma S, Rangesa M, DeWolf S, Elhanati Y, Perica K, Young JW Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.. Blood advances. 2022; 6(5); 1547-1558. [PubMed: 35100339].
-
Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.. Human vaccines & immunotherapeutics. 2022; 18(6); 2105067. [PubMed: 35997582].
-
Gosavi D, Wower I, Beckmann IK, Hofacker IL, Wower J, Wolfinger MT, Sztuba-Solinska J Insights into the secondary and tertiary structure of the Bovine Viral Diarrhea Virus Internal Ribosome Entry Site.. RNA biology. 2022; 19(1); 496-506. [PubMed: 35380920].
-
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases [https://clinicaltrials.gov/study/NCT03412786]
-
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer [https://clinicaltrials.gov/study/NCT05559177]
-
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [https://clinicaltrials.gov/study/NCT00373217]
-
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen [https://clinicaltrials.gov/study/NCT00623831]
-
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer [https://clinicaltrials.gov/study/NCT05227378]
-
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC [https://clinicaltrials.gov/study/NCT05317325]
-
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT03047928]
-
Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) (PerCellVac3) [https://clinicaltrials.gov/study/NCT02808416]
-
PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO) (OBERTO) [https://clinicaltrials.gov/study/NCT03391232]
-
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (WOKVAC) [https://clinicaltrials.gov/study/NCT02780401]
-
A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT05202561]
-
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) [https://clinicaltrials.gov/study/NCT02851056]
-
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors [https://clinicaltrials.gov/study/NCT05235607]
-
Backlund CM, Holden RL, Moynihan KD, Garafola D, Farquhar C, Mehta NK, Maiorino L, Pham S, Iorgulescu JB, Reardon DA, Wu CJ, Pentelute BL, Irvine DJ Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity.. Proceedings of the National Academy of Sciences of the United States of America. 2022; 119(32); e2204078119. [PubMed: 35914154].
-
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.. Blood advances. 2022; 6(7); 2183-2194. [PubMed: 34807983].
-
GVAX vs. Placebo for MDS/AML After Allo HSCT [https://clinicaltrials.gov/study/NCT01773395]
-
Jie J, Liu G, Feng J, Huo D, Wu Y, Yuan H, Tai G, Ni W MF59 Promoted the Combination of CpG ODN1826 and MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC Maturation by Prolonging the Local Retention Time of Antigen and Down-Regulating of IL-6/STAT3.. International journal of molecular sciences. 2022; 23(18); . [PubMed: 36142800].
-
Zhou SH, Li YT, Zhang RY, Liu YL, You ZW, Bian MM, Wen Y, Wang J, Du JJ, Guo J Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.. Frontiers in immunology. 2022; 13; 857779. [PubMed: 35371101].
-
Zhang S, Liu Y, Zhou J, Wang J, Jin G, Wang X Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects.. International journal of molecular sciences. 2022; 23(23); . [PubMed: 36499455].
-
Du JJ, Zhou SH, Cheng ZR, Xu WB, Zhang RY, Wang LS, Guo J MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.. Frontiers in chemistry. 2022; 10; 814880. [PubMed: 35186882].
-
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe) [https://clinicaltrials.gov/study/NCT00626483]
-
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer [https://clinicaltrials.gov/study/NCT05023928]
-
Vaccination Plus Ontak in Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00515528]
-
Liu Y, Wang Z, Yu F, Li M, Zhu H, Wang K, Meng M, Zhao W The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.. International journal of nanomedicine. 2021; 16; 403-420. [PubMed: 33469292].
-
Wu X, McFall-Boegeman H, Rashidijahanabad Z, Liu K, Pett C, Yu J, Schorlemer M, Ramadan S, Behren S, Westerlind U, Huang X Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate.. Organic & biomolecular chemistry. 2021; 19(11); 2448-2455. [PubMed: 33645601].
-
Gao Y, Zhao Q, Dong H, Xiao M, Huang X, Wu X Developing Acid-Responsive Glyco-Nanoplatform Based Vaccines for Enhanced Cytotoxic T-lymphocyte Responses Against Cancer and SARS-CoV-2.. Advanced functional materials. 2021; 31(41); 2105059. [PubMed: 34512228].
-
Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GE Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.. Clinical immunology (Orlando, Fla.). 2021; 225; 108679. [PubMed: 33485895].
-
Barton KN, Siddiqui F, Pompa R, Freytag SO, Khan G, Dobrosotskaya I, Ajlouni M, Zhang Y, Cheng J, Movsas B, Kwon D Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer.. Molecular therapy oncolytics. 2021; 20; 94-9104. [PubMed: 33575474].
-
Teplensky MH, Dittmar JW, Qin L, Wang S, Evangelopoulos M, Zhang B, Mirkin CA Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets.. Advanced healthcare materials. 2021; 10(22); e2101262. [PubMed: 34494382].
-
Li T, Zhao L, Yang Y, Wang Y, Zhang Y, Guo J, Chen G, Qin P, Xu B, Ma B, Zhang F, Shang Y, Li Q, Zhang K, Yuan D, Feng C, Ma Y, Liu Z, Tian Z, Li H, Wang S, Gao Q T Cells Expanded from PD-1(+) Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes.. Cancer research. 2021; 81(8); 2184-2194. [PubMed: 33408117].
-
Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, Chintakuntlawar AV, Pawlicki J, Sylvester AJ, McMullan T, Samuels R, Kim JJ, Weiner D, Boyer JD, Morrow MP, Humeau L, Skolnik JM Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.. Journal for immunotherapy of cancer. 2021; 9(7); . [PubMed: 34230114].
-
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer [https://clinicaltrials.gov/study/NCT02018458]
-
FRAME-001 Personalized Vaccine in NSCLC [https://clinicaltrials.gov/study/NCT04998474]
-
Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, Boyer J, Skolnik J, Esser M, Kumar R, Bagarazzi M, Weichselbaum R, Spiotto M A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.. International journal of radiation oncology, biology, physics. 2020; 107(3); 487-498. [PubMed: 32151670].
-
Sato-Dahlman M, LaRocca CJ, Yanagiba C, Yamamoto M Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.. Cancers. 2020; 12(5); . [PubMed: 32455560].
-
Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.. Breast cancer research and treatment. 2020; 181(2); 391-401. [PubMed: 32323103].
-
Czerwinska P, Rucinski M, Wlodarczyk N, Jaworska A, Grzadzielewska I, Gryska K, Galus L, Mackiewicz J, Mackiewicz A Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6.. Oncoimmunology. 2020; 9(1); 1710063. [PubMed: 32002306].
-
Toyoda T, Kamata T, Tanaka K, Ihara F, Takami M, Suzuki H, Nakajima T, Ikeuchi T, Kawasaki Y, Hanaoka H, Nakayama T, Yoshino I, Motohashi S Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.. Journal for immunotherapy of cancer. 2020; 8(1); . [PubMed: 32188702].
-
Kyriakopoulos CE, Eickhoff JC, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, McNeel DG Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020; 26(19); 5162-5171. [PubMed: 32513836].
-
Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.. The Journal of experimental medicine. 2020; 217(9); . [PubMed: 32558897].
-
Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM CD8(+) T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.. Molecular therapy : the journal of the American Society of Gene Therapy. 2020; 28(5); 1238-1250. [PubMed: 32208168].
-
Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer.. The Journal of clinical investigation. 2020; 130(11); 5976-5988. [PubMed: 33016924].
-
Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020; 26(5); 845-854. [PubMed: 32018062].
-
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) [https://clinicaltrials.gov/study/NCT01094496]
-
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer [https://clinicaltrials.gov/study/NCT00004880]
-
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia [https://clinicaltrials.gov/study/NCT00301093]
-
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation [https://clinicaltrials.gov/study/NCT00809250]
-
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination [https://clinicaltrials.gov/study/NCT00442130]
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer [https://clinicaltrials.gov/study/NCT00091286]
-
Vaccine Treatment for Advanced Breast Cancer [https://clinicaltrials.gov/study/NCT00090480]
-
Vaccine Treatment for Advanced Malignant Melanoma [https://clinicaltrials.gov/study/NCT00300612]
-
Vaccine Treatment for Hormone Refractory Prostate Cancer [https://clinicaltrials.gov/study/NCT00105053]
-
Immune Modulatory DC Vaccine Against Brain Tumor [https://clinicaltrials.gov/study/NCT03914768]
-
"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT04317248]
-
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer [https://clinicaltrials.gov/study/NCT03480152]
-
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (AZACTA) [https://clinicaltrials.gov/study/NCT02750995]
-
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer [https://clinicaltrials.gov/study/NCT01312376]
-
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer [https://clinicaltrials.gov/study/NCT00343109]
-
Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer (Auto TAG) [https://clinicaltrials.gov/study/NCT00684294]
-
Kuai R, Singh PB, Sun X, Xu C, Najafabadi AH, Scheetz L, Yuan W, Xu Y, Hong H, Keskin DB, Wu CJ, Jain R, Schwendeman A, Moon JJ Robust anti-tumor T cell response with efficient intratumoral infiltration by nanodisc cancer immunotherapy.. Advanced therapeutics. 2020; 3(9); . [PubMed: 38317797].
-
Hossain MK, Vartak A, Sucheck SJ, Wall KA Synthesis and Immunological Evaluation of a Single Molecular Construct MUC1 Vaccine Containing l-Rhamnose Repeating Units.. Molecules (Basel, Switzerland). 2020; 25(14); . [PubMed: 32659971].
-
Guo M, Luo B, Pan M, Li M, Zhao F, Dou J MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine.. International immunopharmacology. 2020; 85; 106631. [PubMed: 32470879].
-
Bermejo IA, Navo CD, Castro-López J, Guerreiro A, Jiménez-Moreno E, Sánchez Fernández EM, García-Martín F, Hinou H, Nishimura SI, García Fernández JM, Mellet CO, Avenoza A, Busto JH, Bernardes GJL, Hurtado-Guerrero R, Peregrina JM, Corzana F Synthesis, conformational analysis and in vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp(2)-iminosugar fragment.. Chemical science. 2020; 11(15); 3996-4006. [PubMed: 34122869].
-
Spadaro A, Basile L, Pappalardo M, Bonaccorso C, Rao M, Ronsisvalle S, Granata G, Guccione S Quantum Chemical and Molecular Dynamics Studies of MUC1 Calix[4,8]arene Scaffold Based Anticancer Vaccine Candidates.. Journal of chemical information and modeling. 2020; 60(10); 5162-5171. [PubMed: 32818373].
-
Du JJ, Wang CW, Xu WB, Zhang L, Tang YK, Zhou SH, Gao XF, Yang GF, Guo J Multifunctional Protein Conjugates with Built-in Adjuvant (Adjuvant-Protein-Antigen) as Cancer Vaccines Boost Potent Immune Responses.. iScience. 2020; 23(3); 100935. [PubMed: 32146328].
-
Liu Y, Tang L, Gao N, Diao Y, Zhong J, Deng Y, Wang Z, Jin G, Wang X Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects.. Oncology letters. 2020; 20(3); 2369-2377. [PubMed: 32782554].
-
Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).. European journal of cancer (Oxford, England : 1990). 2020; 132; 43-52. [PubMed: 32325419].
-
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer [https://clinicaltrials.gov/study/NCT03166254]
-
Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma (cholangio) [https://clinicaltrials.gov/study/NCT03042182]
-
Open Label Immunotherapy Trial for Ovarian Cancer (V3-OVA) [https://clinicaltrials.gov/study/NCT03556566]
-
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) [https://clinicaltrials.gov/study/NCT00840931]
-
Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.. Cancer immunology, immunotherapy : CII. 2019; 68(3); 421-432. [PubMed: 30564891].
-
Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer [https://clinicaltrials.gov/study/NCT03871205]
-
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms [https://clinicaltrials.gov/study/NCT03468244]
-
Li M, Wang Z, Yan B, Yin X, Zhao Y, Yu F, Meng M, Liu Y, Zhao W Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.. MedChemComm. 2019; 10(12); 2073-2077. [PubMed: 32133105].
-
Du JJ, Zou SY, Chen XZ, Xu WB, Wang CW, Zhang L, Tang YK, Zhou SH, Wang J, Yin XG, Gao XF, Liu Z, Guo J Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.. Chemistry, an Asian journal. 2019; 14(12); 2116-2121. [PubMed: 31042017].
-
Wu X, McKay C, Pett C, Yu J, Schorlemer M, Ramadan S, Lang S, Behren S, Westerlind U, Finn MG, Huang X Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.. ACS chemical biology. 2019; 14(10); 2176-2184. [PubMed: 31498587].
-
Compañón I, Guerreiro A, Mangini V, Castro-López J, Escudero-Casao M, Avenoza A, Busto JH, Castillón S, Jiménez-Barbero J, Asensio JL, Jiménez-Osés G, Boutureira O, Peregrina JM, Hurtado-Guerrero R, Fiammengo R, Bernardes GJL, Corzana F Structure-Based Design of Potent Tumor-Associated Antigens: Modulation of Peptide Presentation by Single-Atom O/S or O/Se Substitutions at the Glycosidic Linkage.. Journal of the American Chemical Society. 2019; 141(9); 4063-4072. [PubMed: 30726084].
-
Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).. Oncoimmunology. 2019; 8(8); 1615817. [PubMed: 31413923].
-
Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.. Journal for immunotherapy of cancer. 2019; 7(1); 90. [PubMed: 30922362].
-
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.. Journal for immunotherapy of cancer. 2019; 7(1); 6. [PubMed: 30626434].
-
Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.. Frontiers in immunology. 2019; 10; 766. [PubMed: 31031762].
-
Hossain MK, Vartak A, Sucheck SJ, Wall KA Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity.. ACS omega. 2019; 4(3); 5204-5208. [PubMed: 30949616].
-
Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B, Liu Q Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects.. Translational oncology. 2019; 12(5); 733-738. [PubMed: 30877975].
-
Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.. Oncoimmunology. 2019; 8(1); e1512329. [PubMed: 30546947].
-
Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.. Journal for immunotherapy of cancer. 2019; 7(1); 163. [PubMed: 31248461].
-
Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.. Cancer immunology, immunotherapy : CII. 2019; 68(7); 1211-1222. [PubMed: 31069460].
-
Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019; 25(19); 5799-5807. [PubMed: 31320597].
-
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC-BC-819) [https://clinicaltrials.gov/study/NCT01413087]
-
Personalized DC Vaccine for Postoperative Cancer [https://clinicaltrials.gov/study/NCT04147078]
-
Mitchell D, Chintala S, Dey M Plasmacytoid dendritic cell in immunity and cancer.. Journal of neuroimmunology. 2018; 322; 63-73. [PubMed: 30049538].
-
Lee SJ, Kim HJ, Huh YM, Kim IW, Jeong JH, Kim JC, Kim JD Functionalized Magnetic PLGA Nanospheres for Targeting and Bioimaging of Breast Cancer.. Journal of nanoscience and nanotechnology. 2018; 18(3); 1542-1547. [PubMed: 29448628].
-
Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(6); 1315-1325. [PubMed: 29301826].
-
Mohammadzadeh M, Shirmohammadi M, Ghojazadeh M, Nikniaz L, Raeisi M, Aghdas SAM Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis.. Prostate international. 2018; 6(4); 119-125. [PubMed: 30505813].
-
Xing P, Wang H, Yang S, Han X, Sun Y, Shi Y Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.. BMC immunology. 2018; 19(1); 14. [PubMed: 29661145].
-
Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.. Journal for immunotherapy of cancer. 2018; 6(1); 38. [PubMed: 29773080].
-
Pektor S, Hilscher L, Walzer KC, Miederer I, Bausbacher N, Loquai C, Schreckenberger M, Sahin U, Diken M, Miederer M In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET.. EJNMMI research. 2018; 8(1); 80. [PubMed: 30112704].
-
Ravindranathan S, Nguyen KG, Kurtz SL, Frazier HN, Smith SG, Koppolu BP, Rajaram N, Zaharoff DA Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.. Breast cancer research : BCR. 2018; 20(1); 126. [PubMed: 30348199].
-
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.. Oncoimmunology. 2018; 7(4); e1303584. [PubMed: 29632710].
-
Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.. JAMA oncology. 2018; 4(12); e183267. [PubMed: 30128502].
-
Flickinger JC Jr, Rodeck U, Snook AE <i>Listeria monocytogenes</i> as a Vector for Cancer Immunotherapy: Current Understanding and Progress.. Vaccines. 2018; 6(3); . [PubMed: 30044426].
-
Kwiatkowska-Borowczyk E, Czerwińska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, Przybyła A, Kozłowska AK, Galus Å, Kwinta Å, Dondajewska E, Gąbka-Buszek A, Żakowska M, Mackiewicz A Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients.. Oncoimmunology. 2018; 7(11); e1509821. [PubMed: 30377573].
-
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.. Frontiers in immunology. 2018; 9; 947. [PubMed: 29770138].
-
Saxena M, Bhardwaj N Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.. Trends in cancer. 2018; 4(2); 119-137. [PubMed: 29458962].
-
Sun L, Hao Y, Wang Z, Zeng Y Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.. Viruses. 2018; 10(4); . [PubMed: 29570629].
-
Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Schölch S, Reissfelder C, Weitz J, Schneider M, Wiemann S, Momburg F, Beckhove P Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.. Oncoimmunology. 2018; 7(12); e1500671. [PubMed: 30524892].
-
Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer.. Oncotarget. 2018; 9(11); 10110-10117. [PubMed: 29515795].
-
Qiu J, Peng S, Ma Y, Yang A, Farmer E, Cheng MA, Roden RBS, Wu TC, Chang YN, Hung CF Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.. Virology. 2018; 525; 205-215. [PubMed: 30296681].
-
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant [https://clinicaltrials.gov/study/NCT01174082]
-
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206) [https://clinicaltrials.gov/study/NCT00466726]
-
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT00056134]
-
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma [https://clinicaltrials.gov/study/NCT00478062]
-
Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer [https://clinicaltrials.gov/study/NCT00868114]
-
MUC1 Vaccine for Triple-negative Breast Cancer [https://clinicaltrials.gov/study/NCT00986609]
-
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma [https://clinicaltrials.gov/study/NCT00923351]
-
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs [https://clinicaltrials.gov/study/NCT02332889]
-
Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (MEL39) [https://clinicaltrials.gov/study/NCT00938223]
-
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma [https://clinicaltrials.gov/study/NCT00101166]
-
A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT03674073]
-
Hossain MK, Vartak A, Karmakar P, Sucheck SJ, Wall KA Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies.. ACS chemical biology. 2018; 13(8); 2130-2142. [PubMed: 29916701].
-
Wang H, Yang B, Wang Y, Liu F, Fernández-Tejada A, Dong S β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine.. Chemical communications (Cambridge, England). 2018; 55(2); 253-256. [PubMed: 30534737].
-
McDonald DM, Hanna CC, Ashhurst AS, Corcilius L, Byrne SN, Payne RJ Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.. ACS chemical biology. 2018; 13(12); 3279-3285. [PubMed: 30359529].
-
Glaffig M, Stergiou N, Hartmann S, Schmitt E, Kunz H A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells.. ChemMedChem. 2018; 13(1); 25-29. [PubMed: 29193802].
-
Li M, Yu F, Yao C, Wang PG, Liu Y, Zhao W Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.. Organic & biomolecular chemistry. 2018; 16(6); 993-999. [PubMed: 29345713].
-
Liu C, Lu Z, Xie Y, Guo Q, Geng F, Sun B, Wu H, Yu B, Wu J, Zhang H, Yu X, Kong W Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.. Immunology letters. 2018; 200; 33-42. [PubMed: 29894719].
-
Supekar NT, Lakshminarayanan V, Capicciotti CJ, Sirohiwal A, Madsen CS, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.. Chembiochem : a European journal of chemical biology. 2018; 19(2); 121-125. [PubMed: 29120508].
-
Wu X, Yin Z, McKay C, Pett C, Yu J, Schorlemer M, Gohl T, Sungsuwan S, Ramadan S, Baniel C, Allmon A, Das R, Westerlind U, Finn MG, Huang X Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.. Journal of the American Chemical Society. 2018; 140(48); 16596-16609. [PubMed: 30398345].
-
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma [https://clinicaltrials.gov/study/NCT00683670]
-
Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA [https://clinicaltrials.gov/study/NCT00148928]
-
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery [https://clinicaltrials.gov/study/NCT02944357]
-
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation [https://clinicaltrials.gov/study/NCT00405327]
-
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ An immunogenic personal neoantigen vaccine for patients with melanoma.. Nature. 2017; 547(7662); 217-221. [PubMed: 28678778].
-
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT02510950]
-
Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ, Tang YQ, Chen RF Optimized construction of MUC1-VNTR(n) DNA vaccine and its anti-pancreatic cancer efficacy.. Oncology letters. 2017; 13(4); 2198-2206. [PubMed: 28454381].
-
Stergiou N, Glaffig M, Jonuleit H, Schmitt E, Kunz H Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.. ChemMedChem. 2017; 12(17); 1424-1428. [PubMed: 28675699].
-
Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.. Leukemia. 2017; 31(3); 697-704. [PubMed: 27654852].
-
Li J, Chen J, Li X, Qian Y Vaccination efficacy with marrow mesenchymal stem cell against cancer was enhanced under simulated microgravity.. Biochemical and biophysical research communications. 2017; 485(3); 606-613. [PubMed: 28238782].
-
Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.. Cancer immunology, immunotherapy : CII. 2017; 66(7); 891-901. [PubMed: 28391357].
-
Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia.. Cancer immunology, immunotherapy : CII. 2017; 66(7); 851-863. [PubMed: 28321480].
-
Gyurkocza B, Lazarus HM, Giralt S Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.. Bone marrow transplantation. 2017; 52(8); 1083-1090. [PubMed: 28244979].
-
Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S Immunotherapy in Gastrointestinal Cancers.. BioMed research international. 2017; 2017; 4346576. [PubMed: 28758114].
-
Escribà-Garcia L, Alvarez-Fernández C, Tellez-Gabriel M, Sierra J, Briones J Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.. Journal of translational medicine. 2017; 15(1); 115. [PubMed: 28549432].
-
Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE Personalized cancer vaccines: Targeting the cancer mutanome.. Vaccine. 2017; 35(7); 1094-1100. [PubMed: 27449681].
-
Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA A Genetically Modified attenuated <i>Listeria</i> Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.. Frontiers in cellular and infection microbiology. 2017; 7; 279. [PubMed: 28706878].
-
Weinstock M, Rosenblatt J, Avigan D Dendritic Cell Therapies for Hematologic Malignancies.. Molecular therapy. Methods & clinical development. 2017; 5; 66-75. [PubMed: 28480306].
-
Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.. Cancer immunology, immunotherapy : CII. 2017; 66(10); 1345-1357. [PubMed: 28608115].
-
Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017; 23(16); 4556-4568. [PubMed: 28468947].
-
Nitschke NJ, Bjoern J, Iversen TZ, Andersen MH, Svane IM Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.. Stem cell investigation. 2017; 4; 77. [PubMed: 29057249].
-
Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.. Journal for immunotherapy of cancer. 2017; 5; 4. [PubMed: 28116088].
-
Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, Xiao F, Bai Z, Yao H, Ma X, Jin L, Wu C, Seth P, Zhang Z, Wang L An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.. Human gene therapy. 2017; 28(8); 667-680. [PubMed: 28530155].
-
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.. The Lancet. Oncology. 2017; 18(10); 1373-1385. [PubMed: 28844499].
-
Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017; 35(30); 3410-3416. [PubMed: 28834453].
-
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) [https://clinicaltrials.gov/study/NCT02493829]
-
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma [https://clinicaltrials.gov/study/NCT01241162]
-
Multiple Antigen-Engineered DC Vaccine for Melanoma [https://clinicaltrials.gov/study/NCT01622933]
-
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma [https://clinicaltrials.gov/study/NCT00625755]
-
Vaccination With Tetanus and KLH to Assess Immune Responses [https://clinicaltrials.gov/study/NCT00000105]
-
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma [https://clinicaltrials.gov/study/NCT02745756]
-
Yano S, Takehara K, Tazawa H, Kishimoto H, Urata Y, Kagawa S, Fujiwara T, Hoffman RM Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam®-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging.. PloS one. 2016; 11(9); e0162991. [PubMed: 27673332].
-
Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.. Vaccine. 2016; 34(6); 757-761. [PubMed: 26772631].
-
Pujol JL, De Pas T, Rittmeyer A, Vallières E, Kubisa B, Levchenko E, Wiesemann S, Masters GA, Shen R, Tjulandin SA, Hofmann HS, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016; 11(12); 2208-2217. [PubMed: 27544054].
-
Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.. Breast cancer research and treatment. 2016; 156(2); 301-310. [PubMed: 26975189].
-
Gatson NT, Weathers SP, de Groot JF ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.. CNS oncology. 2016; 5(1); 11-26. [PubMed: 26670466].
-
Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).. Gynecologic oncology. 2016; 140(2); 245-252. [PubMed: 26616223].
-
Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.. The Lancet. Oncology. 2016; 17(11); 1599-1611. [PubMed: 27720136].
-
Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, Bartlett DL Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.. Molecular therapy : the journal of the American Society of Gene Therapy. 2016; 24(8); 1492-1501. [PubMed: 27203445].
-
Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.. Cancer immunology research. 2016; 4(9); 766-778. [PubMed: 27364122].
-
McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG Pancreatic cancer: Update on immunotherapies and algenpantucel-L.. Human vaccines & immunotherapeutics. 2016; 12(3); 563-575. [PubMed: 26619245].
-
LoGuidice A, Houlihan A, Deans R Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process.. Journal of tissue engineering. 2016; 7; 2041731416656148. [PubMed: 27493716].
-
Garfall AL, Stadtmauer EA Cellular and vaccine immunotherapy for multiple myeloma.. Hematology. American Society of Hematology. Education Program. 2016; 2016(1); 521-527. [PubMed: 27913524].
-
Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.. Oncoimmunology. 2016; 5(9); e1207842. [PubMed: 27757300].
-
Elster JD, Krishnadas DK, Lucas KG Dendritic cell vaccines: A review of recent developments and their potential pediatric application.. Human vaccines & immunotherapeutics. 2016; 12(9); 2232-2239. [PubMed: 27245943].
-
Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.. Scientific reports. 2016; 6; 31740. [PubMed: 27545199].
-
Kim SW, Goedegebuure P, Gillanders WE Mammaglobin-A is a target for breast cancer vaccination.. Oncoimmunology. 2016; 5(2); e1069940. [PubMed: 27057470].
-
Eger C, Siebert N, Seidel D, Zumpe M, Jüttner M, Brandt S, Müller HP, Lode HN Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.. PloS one. 2016; 11(3); e0150479. [PubMed: 26967324].
-
Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.. Immunotherapy. 2016; 8(2); 117-125. [PubMed: 26787078].
-
Ottensmeier C, Bowers M, Hamid D, Maishman T, Regan S, Wood W, Cazaly A, Stanton L Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN).. NIHR Journals Library. 2016; ; . [PubMed: 27099895].
-
Gabri MR, Cacciavillano W, Chantada GL, Alonso DF Racotumomab for treating lung cancer and pediatric refractory malignancies.. Expert opinion on biological therapy. 2016; 16(4); 573-578. [PubMed: 26903265].
-
Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.. Cancer immunology, immunotherapy : CII. 2016; 65(11); 1339-1352. [PubMed: 27576783].
-
Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.. Oncoimmunology. 2016; 5(8); e1197459. [PubMed: 27622067].
-
Kim H, Seo EH, Lee SH, Kim BJ The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide.. International journal of molecular sciences. 2016; 17(12); . [PubMed: 27941629].
-
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid [https://clinicaltrials.gov/study/NCT01349647]
-
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT01189383]
-
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant [https://clinicaltrials.gov/study/NCT02115126]
-
Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) [https://clinicaltrials.gov/study/NCT02419170]
-
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma [https://clinicaltrials.gov/study/NCT00004104]
-
Lakshminarayanan V, Supekar NT, Wei J, McCurry DB, Dueck AC, Kosiorek HE, Trivedi PP, Bradley JM, Madsen CS, Pathangey LB, Hoelzinger DB, Wolfert MA, Boons GJ, Cohen PA, Gendler SJ MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.. PloS one. 2016; 11(1); e0145920. [PubMed: 26788922].
-
Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.. Cancer immunology research. 2016; 4(10); 881-892. [PubMed: 27604597].
-
Palitzsch B, Gaidzik N, Stergiou N, Stahn S, Hartmann S, Gerlitzki B, Teusch N, Flemming P, Schmitt E, Kunz H A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer.. Angewandte Chemie (International ed. in English). 2016; 55(8); 2894-2898. [PubMed: 26800384].
-
Martínez-Sáez N, Supekar NT, Wolfert MA, Bermejo IA, Hurtado-Guerrero R, Asensio JL, Jiménez-Barbero J, Busto JH, Avenoza A, Boons GJ, Peregrina JM, Corzana F Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment.. Chemical science. 2016; 7(3); 2294-2301. [PubMed: 29910919].
-
Cai H, Degliangeli F, Palitzsch B, Gerlitzki B, Kunz H, Schmitt E, Fiammengo R, Westerlind U Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.. Bioorganic & medicinal chemistry. 2016; 24(5); 1132-1135. [PubMed: 26853835].
-
Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.. The Lancet. Oncology. 2016; 17(2); 212-223. [PubMed: 26727163].
-
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer [https://clinicaltrials.gov/study/NCT00660101]
-
Hartmann S, Nuhn L, Palitzsch B, Glaffig M, Stergiou N, Gerlitzki B, Schmitt E, Kunz H, Zentel R CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines.. Advanced healthcare materials. 2015; 4(4); 522-527. [PubMed: 25327631].
-
Carmon L, Avivi I, Kovjazin R, Zuckerman T, Dray L, Gatt ME, Or R, Shapira MY Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.. British journal of haematology. 2015; 169(1); 44-56. [PubMed: 25496030].
-
Johannes M, Reindl M, Gerlitzki B, Schmitt E, Hoffmann-Röder A Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.. Beilstein journal of organic chemistry. 2015; 11; 155-161. [PubMed: 25670999].
-
Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.. Chemical communications (Cambridge, England). 2015; 51(50); 10214-10217. [PubMed: 26022217].
-
Freytag SO, Zhang Y, Siddiqui F Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.. Molecular therapy oncolytics. 2015; 2; . [PubMed: 26767191].
-
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.. Oncotarget. 2015; 6(31); 32228-32243. [PubMed: 26334096].
-
Fujio K, Watanabe M, Ueki H, Li SA, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y, Kumon H A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment.. Oncology reports. 2015; 33(4); 1585-1592. [PubMed: 25632844].
-
Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.. PloS one. 2015; 10(10); e0140483. [PubMed: 26492414].
-
Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.. American journal of hematology. 2015; 90(7); 602-607. [PubMed: 25802083].
-
Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.. mAbs. 2015; 7(3); 584-604. [PubMed: 25875246].
-
Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.. Oncoimmunology. 2015; 4(8); e1019197. [PubMed: 26405571].
-
Balint JP, Gabitzsch ES, Rice A, Latchman Y, Xu Y, Messerschmidt GL, Chaudhry A, Morse MA, Jones FR Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.. Cancer immunology, immunotherapy : CII. 2015; 64(8); 977-987. [PubMed: 25956394].
-
Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, Grossi F Belagenpumatucel-L for the treatment of non-small cell lung cancer.. Expert opinion on biological therapy. 2015; 15(9); 1371-1379. [PubMed: 26211534].
-
Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.. Journal for immunotherapy of cancer. 2015; 3; 14. [PubMed: 25901286].
-
Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.. Vaccine. 2015; 33(38); 4798-4806. [PubMed: 26241951].
-
Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.. Oncoimmunology. 2015; 4(8); e1026529. [PubMed: 26405584].
-
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer [https://clinicaltrials.gov/study/NCT02074046]
-
Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.. Immunotherapy. 2014; 6(5); 519-531. [PubMed: 24896623].
-
Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.. Cancer immunology research. 2014; 2(10); 949-961. [PubMed: 25116755].
-
James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, Griffith TS CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.. Cancer immunology, immunotherapy : CII. 2014; 63(11); 1213-1227. [PubMed: 25143233].
-
Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.. Oncoimmunology. 2014; 3(11); e956012. [PubMed: 25941588].
-
Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.. Oncoimmunology. 2014; 3(11); e963406. [PubMed: 25941591].
-
Hannu K, Johanna M, Ulf-Håkan S KLK-targeted Therapies for Prostate Cancer.. EJIFCC. 2014; 25(2); 207-218. [PubMed: 27683469].
-
Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, Yoshida K, Tsunoda T, Ikeda T, Nakamura Y, Okinaga K Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.. Journal of translational medicine. 2014; 12; 84. [PubMed: 24708624].
-
Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R, Li JJ Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.. PloS one. 2014; 9(4); e93886. [PubMed: 24699863].
-
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(5); 1355-1365. [PubMed: 24520093].
-
Gajdosik Z Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.. Drugs of today (Barcelona, Spain : 1998). 2014; 50(4); 301-307. [PubMed: 24918647].
-
Kato Y [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers].. Gan to kagaku ryoho. Cancer & chemotherapy. 2014; 41(10); 1280-1282. [PubMed: 25335717].
-
Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL Phase I dendritic cell p53 peptide vaccine for head and neck cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(9); 2433-2444. [PubMed: 24583792].
-
Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, Whelan RJ, Patankar MS MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.. Molecular cancer. 2014; 13; 129. [PubMed: 24886523].
-
Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.. Journal for immunotherapy of cancer. 2014; 2; 4. [PubMed: 24829761].
-
Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.. Prostate cancer and prostatic diseases. 2014; 17(3); 259-264. [PubMed: 24957547].
-
Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.. Vaccine. 2014; 32(8); 957-964. [PubMed: 24397899].
-
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma [https://clinicaltrials.gov/study/NCT00085189]
-
Fritsch EF, Hacohen N, Wu CJ Personal neoantigen cancer vaccines: The momentum builds.. Oncoimmunology. 2014; 3; e29311. [PubMed: 25101225].
-
Cai H, Sun ZY, Chen MS, Zhao YF, Kunz H, Li YM Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.. Angewandte Chemie (International ed. in English). 2014; 53(6); 1699-1703. [PubMed: 24449389].
-
Palitzsch B, Hartmann S, Stergiou N, Glaffig M, Schmitt E, Kunz H A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.. Angewandte Chemie (International ed. in English). 2014; 53(51); 14245-14249. [PubMed: 25318465].
-
Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, Suehiro Y, Yamasaki T, Hinoda Y, Oka M Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.. Journal of translational medicine. 2014; 12; 175. [PubMed: 24947606].
-
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.. The Lancet. Oncology. 2014; 15(1); 59-68. [PubMed: 24331154].
-
Burkhardt UE, Wu CJ Boosting leukemia-specific T cell responses in patients following stem cell transplantation.. Oncoimmunology. 2013; 2(11); e26587. [PubMed: 24482749].
-
Cai H, Sun ZY, Huang ZH, Shi L, Zhao YF, Kunz H, Li YM Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.. Chemistry (Weinheim an der Bergstrasse, Germany). 2013; 19(6); 1962-1970. [PubMed: 23280874].
-
Geraci C, Consoli GM, Granata G, Galante E, Palmigiano A, Pappalardo M, Di Puma SD, Spadaro A First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: synthesis and biological evaluation.. Bioconjugate chemistry. 2013; 24(10); 1710-1720. [PubMed: 24041198].
-
Cai H, Chen MS, Sun ZY, Zhao YF, Kunz H, Li YM Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.. Angewandte Chemie (International ed. in English). 2013; 52(23); 6106-6110. [PubMed: 23616304].
-
Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.. Cancer prevention research (Philadelphia, Pa.). 2013; 6(1); 18-26. [PubMed: 23248097].
-
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission [https://clinicaltrials.gov/study/NCT01982487?term=NCT01982487&viewType=Table&rank=1]
-
Xu G, Smith T, Grey F, Hill AB Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.. Biochemical and biophysical research communications. 2013; 437(2); 287-291. [PubMed: 23811402].
-
Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(15); 4228-4238. [PubMed: 23653149].
-
Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.. Cancer research. 2013; 73(12); 3545-3554. [PubMed: 23539449].
-
Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL).. BioMed research international. 2013; 2013; 976383. [PubMed: 23509826].
-
Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, Liu LN, Peshwa MV Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.. International immunopharmacology. 2013; 15(3); 488-497. [PubMed: 23474736].
-
Freytag SO, Barton KN, Zhang Y Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.. Gene therapy. 2013; 20(12); 1131-1139. [PubMed: 23842593].
-
Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.. Molecular oncology. 2013; 7(3); 484-496. [PubMed: 23333597].
-
Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.. Oncoimmunology. 2013; 2(1); e22664. [PubMed: 23482679].
-
Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.. The Journal of clinical investigation. 2013; 123(9); 3756-3765. [PubMed: 23912587].
-
Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.. Cancer research. 2013; 73(6); 1676-1688. [PubMed: 23348421].
-
Kozłowska A, Mackiewicz J, Mackiewicz A Therapeutic gene modified cell based cancer vaccines.. Gene. 2013; 525(2); 200-207. [PubMed: 23566846].
-
Bedke J, Stenzl A IMA901: a peptide vaccine in renal cell carcinoma.. Expert opinion on investigational drugs. 2013; 22(10); 1329-1336. [PubMed: 23899354].
-
Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial.. Journal of Cancer. 2013; 4(7); 577-584. [PubMed: 23983823].
-
Biological Therapy in Treating Patients With Prostate Cancer [https://clinicaltrials.gov/study/NCT00002637]
-
Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.. Cancer immunology, immunotherapy : CII. 2012; ; . [PubMed: 22729556].
-
Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23(5); 1314-1319. [PubMed: 21930686].
-
Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2012; 35(9); 702-710. [PubMed: 23090079].
-
Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P Virus-like particles induce robust human T-helper cell responses.. European journal of immunology. 2012; 42(2); 330-340. [PubMed: 22057679].
-
Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.. Blood. 2012; 120(15); 3030-3038. [PubMed: 22932804].
-
Miyauchi M, Murata M, Fukushima A, Sato T, Nakagawa M, Fujii T, Koseki N, Chiba N, Kashiwazaki Y Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models.. Drug discoveries & therapeutics. 2012; 6(4); 218-225. [PubMed: 23006993].
-
Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, Plumas J HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.. The Journal of investigative dermatology. 2012; 132(10); 2395-2406. [PubMed: 22696054].
-
Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.. Journal of translational medicine. 2012; 10; 156. [PubMed: 22862954].
-
Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2012; 12(4); 290-299. [PubMed: 22237175].
-
Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL, Qian KQ Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer.. Cancer immunology, immunotherapy : CII. 2012; 61(9); 1415-1424. [PubMed: 22290073].
-
Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.. Oncoimmunology. 2012; 1(3); 287-357. [PubMed: 22737604].
-
Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.. Nature medicine. 2012; 18(8); 1254-1261. [PubMed: 22842478].
-
Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.. Anticancer research. 2012; 32(12); 5201-5209. [PubMed: 23225417].
-
Hanna MG Jr Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer.. Human vaccines & immunotherapeutics. 2012; 8(8); 1156-1160. [PubMed: 22854664].
-
Wilkinson BL, Day S, Chapman R, Perrier S, Apostolopoulos V, Payne RJ Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.. Chemistry (Weinheim an der Bergstrasse, Germany). 2012; 18(51); 16540-16548. [PubMed: 23090901].
-
Huang ZH, Shi L, Ma JW, Sun ZY, Cai H, Chen YX, Zhao YF, Li YM A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.. Journal of the American Chemical Society. 2012; 134(21); 8730-8733. [PubMed: 22587010].
-
Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.. BMC cancer. 2012; 12; 144. [PubMed: 22494623].
-
Tumor Cell Vaccine in Treating Patients With Advanced Cancer [https://clinicaltrials.gov/study/NCT00002505]
-
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes [https://clinicaltrials.gov/study/NCT00393029]
-
Pinkhasov J, Alvarez ML, Rigano MM, Piensook K, Larios D, Pabst M, Grass J, Mukherjee P, Gendler SJ, Walmsley AM, Mason HS Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice.. Plant biotechnology journal. 2011; 9(9); 991-991001. [PubMed: 21740504].
-
Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.. Angewandte Chemie (International ed. in English). 2011; 50(7); 1635-1639. [PubMed: 21308921].
-
Gaidzik N, Kaiser A, Kowalczyk D, Westerlind U, Gerlitzki B, Sinn HP, Schmitt E, Kunz H Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.. Angewandte Chemie (International ed. in English). 2011; 50(42); 9977-9981. [PubMed: 21910197].
-
Choi Y, Jeon YH, Jang JY, Chung JK, Kim CW Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.. Molecular therapy : the journal of the American Society of Gene Therapy. 2011; 19(5); 979-989. [PubMed: 21063392].
-
Hoffmann-Röder A, Johannes M Synthesis of a MUC1-glycopeptide-BSA conjugate vaccine bearing the 3'-deoxy-3'-fluoro-Thomsen-Friedenreich antigen.. Chemical communications (Cambridge, England). 2011; 47(35); 9903-9905. [PubMed: 21818465].
-
Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, Falk M, Murray N Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.. Journal of cancer research and clinical oncology. 2011; 137(9); 1337-1342. [PubMed: 21744082].
-
Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.. The Lancet. Oncology. 2011; 12(12); 1125-1133. [PubMed: 22019520].
-
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.. Cancer immunology, immunotherapy : CII. 2011; 60(2); 261-271. [PubMed: 21069322].
-
Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2011; 25(1); 94-99. [PubMed: 21143299].
-
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(21); 2924-2932. [PubMed: 21690475].
-
Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2011; 34(1); 1-15. [PubMed: 21150709].
-
Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E, Uenishi Y, Kusunose N, Sunagawa M, Yano I, Kashiwazaki Y Arabino-mycolates derived from cell-wall skeleton of Mycobacterium bovis BCG as a prominent structure for recognition by host immunity.. Drug discoveries & therapeutics. 2011; 5(3); 130-135. [PubMed: 22466242].
-
Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.. European journal of immunology. 2011; 41(12); 3553-3563. [PubMed: 22028176].
-
Zhai SQ, Guo W, Hu YY, Yu N, Chen Q, Wang JZ, Fan M, Yang WY Protective effects of brain-derived neurotrophic factor on the noise-damaged cochlear spiral ganglion.. The Journal of laryngology and otology. 2011; 125(5); 449-454. [PubMed: 21078216].
-
Insaidoo FK, Borbulevych OY, Hossain M, Santhanagopolan SM, Baxter TK, Baker BM Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design.. The Journal of biological chemistry. 2011; 286(46); 40163-40173. [PubMed: 21937447].
-
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.. Blood. 2011; 117(3); 788-797. [PubMed: 21030558].
-
Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.. Expert review of vaccines. 2011; 10(6); 755-774. [PubMed: 21692698].
-
Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR Pilot study of 1650-G: a simplified cellular vaccine for lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6(1); 169-173. [PubMed: 21150468].
-
Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.. Journal of immunology (Baltimore, Md. : 1950). 2011; 186(1); 312-322. [PubMed: 21131422].
-
Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2011; 34(7); 556-567. [PubMed: 21760528].
-
Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome.. European journal of immunology. 2011; 41(1); 39-46. [PubMed: 21182075].
-
Park MH, Yang DH, Kim MH, Jang JH, Jang YY, Lee YK, Jin CJ, Pham TN, Thi TA, Lim MS, Lee HJ, Hong CY, Yoon JH, Lee JJ Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer.. Cancer research and treatment : official journal of Korean Cancer Association. 2011; 43(1); 56-66. [PubMed: 21509164].
-
Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.. Blood. 2011; 117(2); 393-402. [PubMed: 21030562].
-
Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.. Cancer investigation. 2011; 29(8); 501-510. [PubMed: 21843052].
-
Parvanova I, Rettig L, Knuth A, Pascolo S The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination.. Vaccine. 2011; 29(22); 3832-3836. [PubMed: 21470580].
-
Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian Y, Shan B Melanoma-associated antigen genes - an update.. Cancer letters. 2011; 302(2); 85-90. [PubMed: 21093980].
-
Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.. Cytotherapy. 2011; 13(9); 1128-1139. [PubMed: 21745159].
-
Liu Y, Tian X, Leitner WW, Aldridge ME, Zheng J, Yu Z, Restifo NP, Weiss R, Scheiblhofer S, Xie C, Sun R, Cheng G, Zeng G Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo.. The Journal of biological chemistry. 2011; 286(43); 37077-37084. [PubMed: 21900253].
-
Idiotypic Vaccination for Follicular Lymphoma Patients (FLIDVAX2006) [https://clinicaltrials.gov/study/NCT00530140]
-
Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.. The Journal of clinical investigation. 2010; 120(2); 533-544. [PubMed: 20071775].
-
Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, Huegli RW, Jacob AL, Heberer M, Oertli D, Marti W, Spagnoli GC, Zajac P Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma.. Molecular therapy : the journal of the American Society of Gene Therapy. 2010; 18(3); 651-659. [PubMed: 19935776].
-
Veltman JD, Lambers ME, van Nimwegen M, de Jong S, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.. Journal of biomedicine & biotechnology. 2010; 2010; 798467. [PubMed: 20508851].
-
Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.. American journal of respiratory and critical care medicine. 2010; 181(12); 1383-1390. [PubMed: 20167848].
-
Akbulut H, Tang Y, Akbulut KG, Maynard J, Deisseroth A Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells.. Gene therapy. 2010; 17(11); 1333-1340. [PubMed: 20596057].
-
Vogel TU, Visan L, Ljutic B, Gajewska B, Caterini J, Salha D, Wen T, He L, Parrington M, Cao SX, McNeil B, Sandhu D, Scollard N, Zhang L, Bradley B, Tang M, Lovitt C, Oomen R, Dunn P, Tartaglia J, Berinstein NL Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8); 743-758. [PubMed: 20842062].
-
Park MY, Kim DR, Jung HW, Yoon HI, Lee JH, Lee CT Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta.. Cancer gene therapy. 2010; 17(5); 356-364. [PubMed: 19893592].
-
Nagayama H, Matsumoto K, Isoo N, Ohno H, Takahashi N, Nakaoka T, Shinozaki M, Watanabe M, Inoue Y, Nagamura F, Oyaizu N, Yamashita N Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer.. Clinical journal of gastroenterology. 2010; 3(6); 307-317. [PubMed: 26190488].
-
Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.. Journal of translational medicine. 2010; 8; 8. [PubMed: 20109232].
-
Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.. Anti-cancer agents in medicinal chemistry. 2010; 10(6); 462-470. [PubMed: 20879986].
-
Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.. Expert opinion on biological therapy. 2010; 10(6); 983-991. [PubMed: 20420527].
-
Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(3); 250-261. [PubMed: 20445345].
-
Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, Ernstoff MS A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16(22); 5548-5556. [PubMed: 20884622].
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF Sipuleucel-T immunotherapy for castration-resistant prostate cancer.. The New England journal of medicine. 2010; 363(5); 411-422. [PubMed: 20818862].
-
Deguchi T, Tanemura M, Miyoshi E, Nagano H, Machida T, Ohmura Y, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Ito T, Mori M, Doki Y, Sawa Y Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.. Cancer research. 2010; 70(13); 5259-5269. [PubMed: 20530670].
-
Hoffmann-Röder A, Kaiser A, Wagner S, Gaidzik N, Kowalczyk D, Westerlind U, Gerlitzki B, Schmitt E, Kunz H Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.. Angewandte Chemie (International ed. in English). 2010; 49(45); 8498-8503. [PubMed: 20878823].
-
Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X, Qin X Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.. BMC cancer. 2009; 9; 191. [PubMed: 19534821].
-
Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.. Investigational new drugs. 2009; 27(4); 379-386. [PubMed: 18931824].
-
Fang J, Lu Y, Ouyang K, Wu G, Zhang H, Liu Y, Chen Y, Lin M, Wang H, Jin L, Cao R, Roque RS, Zong L, Liu J, Li T Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.. Clinical and vaccine immunology : CVI. 2009; 16(7); 1033-1039. [PubMed: 19458203].
-
Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.. Molecular therapy : the journal of the American Society of Gene Therapy. 2009; 17(6); 1101-1108. [PubMed: 19337234].
-
Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(6); 655-666. [PubMed: 19483644].
-
Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.. Molecular immunology. 2009; 46(3); 448-456. [PubMed: 19046770].
-
Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(23); 7375-7380. [PubMed: 19920098].
-
Huang CM Human papillomavirus and vaccination.. Mayo Clinic proceedings. Mayo Clinic. 2008; 83(6); 701-706; quiz 706-706. [PubMed: 18533087].
-
Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(1); 776-784. [PubMed: 18566444].
-
Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.. Cancer research. 2008; 68(3); 861-869. [PubMed: 18245488].
-
Hodge JW, Guha C, Neefjes J, Gulley JL Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.. Oncology (Williston Park, N.Y.). 2008; 22(9); 1064-1070. [PubMed: 18777956].
-
Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(1); 72-80. [PubMed: 18157014].
-
Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.. Annals of surgical oncology. 2008; 15(1); 158-164. [PubMed: 18008108].
-
Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.. Blood. 2008; 112(7); 2956-2964. [PubMed: 18502835].
-
Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.. Human vaccines. 2008; 4(3); 210-218. [PubMed: 18382135].
-
Rice J, Ottensmeier CH, Stevenson FK DNA vaccines: precision tools for activating effective immunity against cancer.. Nature reviews. Cancer. 2008; 8(2); 108-120. [PubMed: 18219306].
-
Tykodi SS, Thompson JA Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.. Expert opinion on biological therapy. 2008; 8(12); 1947-1953. [PubMed: 18990081].
-
Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostböck S, Sabzevari H, Schlom J, Hodge JW Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.. Vaccine. 2008; 26(4); 509-521. [PubMed: 18155327].
-
Karyampudi L, Ghosh SK Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma.. Cellular immunology. 2008; 254(1); 74-80. [PubMed: 18715553].
-
Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(15); 4843-4849. [PubMed: 18676757].
-
Alvarez-Salas LM Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia.. Current opinion in molecular therapeutics. 2008; 10(6); 622-628. [PubMed: 19051140].
-
Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(14); 2292-2298. [PubMed: 18467720].
-
Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.. Clinical immunology (Orlando, Fla.). 2008; 128(2); 148-154. [PubMed: 18508409].
-
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S Functions of natural killer cells.. Nature immunology. 2008; 9(5); 503-510. [PubMed: 18425107].
-
Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(6); 591-598. [PubMed: 18528294].
-
Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.. Cancer research. 2008; 68(23); 9884-9891. [PubMed: 19047169].
-
Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma [https://clinicaltrials.gov/study/NCT00061035]
-
Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.. Cancer therapy. 2008; 6(B); 955-964. [PubMed: 19129927].
-
Jeon YH, Choi Y, Kim HJ, Kang JH, Kim CW, Jeong JM, Lee DS, Chung JK In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination.. Molecular imaging. 2007; 6(5); 297-303. [PubMed: 18092514].
-
Tarp MA, Sørensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.. Glycobiology. 2007; 17(2); 197-209. [PubMed: 17050588].
-
Choi Y, Jeon YH, Kang JH, Chung JK, Schmidt M, Kim AC MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity.. International journal of cancer. Journal international du cancer. 2007; 120(9); 1942-1950. [PubMed: 17266027].
-
Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.. Breast cancer research and treatment. 2007; 106(1); 29-38. [PubMed: 17203384].
-
Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.. The journal of gene medicine. 2007; 9(8); 715-726. [PubMed: 17595048].
-
Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.. Cancer research. 2007; 67(3); 1344-1351. [PubMed: 17283172].
-
Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007; 25(24); 3719-3725. [PubMed: 17704421].
-
Czerniecki BJ, Roses RE, Koski GK Development of vaccines for high-risk ductal carcinoma in situ of the breast.. Cancer research. 2007; 67(14); 6531-6534. [PubMed: 17638860].
-
Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007; 2(10); 957-965. [PubMed: 17909360].
-
Manegold C, Thatcher N Survival improvement in thoracic cancer: progress from the last decade and beyond.. Lung cancer (Amsterdam, Netherlands). 2007; 57 Suppl 2; S3-5. [PubMed: 17686443].
-
Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.. Cytokine & growth factor reviews. 2007; 18(5-6); 389-394. [PubMed: 17692556].
-
Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.. Cancer immunology, immunotherapy : CII. 2007; 56(6); 885-895. [PubMed: 17102977].
-
Tang Y, Lin Z, Ni B, Wei J, Han J, Wang H, Wu Y An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity.. Cancer immunology, immunotherapy : CII. 2007; 56(3); 319-329. [PubMed: 16906394].
-
Harzstark AL, Small EJ Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).. Expert opinion on biological therapy. 2007; 7(8); 1275-1280. [PubMed: 17696825].
-
Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(31); 12837-12842. [PubMed: 17652518].
-
Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL Clinical safety of a viral vector based prostate cancer vaccine strategy.. The Journal of urology. 2007; 178(4 Pt 1); 1515-1520. [PubMed: 17707059].
-
Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.. British journal of cancer. 2006; 95(11); 1474-1482. [PubMed: 17060934].
-
Mincheff M, Zoubak S, Makogonenko Y Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals.. Cancer gene therapy. 2006; 13(4); 436-444. [PubMed: 16276349].
-
Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(29); 4721-4730. [PubMed: 16966690].
-
Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.. Cancer gene therapy. 2006; 13(2); 169-181. [PubMed: 16082381].
-
Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(18); 5503-5510. [PubMed: 17000686].
-
Hirschowitz EA, Hiestand DM, Yannelli JR Vaccines for lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006; 1(1); 93-104. [PubMed: 17409835].
-
DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.. Journal of translational medicine. 2006; 4; 1. [PubMed: 16390546].
-
Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.. AIDS (London, England). 2006; 20(8); 1151-1155. [PubMed: 16691066].
-
Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E Defining MHC class II T helper epitopes for WT1 tumor antigen.. Cancer immunology, immunotherapy : CII. 2006; 55(7); 850-860. [PubMed: 16220325].
-
Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(9); 2817-2825. [PubMed: 16675576].
-
Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.. Journal of virology. 2006; 80(8); 3732-3742. [PubMed: 16571790].
-
Lopes L, Fletcher K, Ikeda Y, Collins M Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.. Cancer immunology, immunotherapy : CII. 2006; 55(8); 1011-1016. [PubMed: 16311731].
-
Trakatelli M, Toungouz M, Blocklet D, Dodoo Y, Gordower L, Laporte M, Vereecken P, Sales F, Mortier L, Mazouz N, Lambermont M, Goldman S, Coulie P, Goldman M, Velu T A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.. Cancer immunology, immunotherapy : CII. 2006; 55(4); 469-474. [PubMed: 16133111].
-
Li D, Li H, Zhang P, Wu X, Wei H, Wang L, Wan M, Deng P, Zhang Y, Wang J, Liu Y, Yu Y, Wang L Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.. European journal of immunology. 2006; 36(5); 1324-1336. [PubMed: 16619287].
-
van Leeuwen EB, Cloosen S, Senden-Gijsbers BL, Agervig Tarp M, Mandel U, Clausen H, Havenga MJ, Duffour MT, García-Vallejo JJ, Germeraad WT, Bos GM Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.. Cytotherapy. 2006; 8(1); 24-35. [PubMed: 16627342].
-
Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.. Glycobiology. 2006; 16(2); 96-9107. [PubMed: 16207894].
-
Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].. Breast cancer research : BCR. 2006; 8(3); R27. [PubMed: 16776849].
-
Dziadek S, Hobel A, Schmitt E, Kunz H A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.. Angewandte Chemie (International ed. in English). 2005; 44(46); 7630-7635. [PubMed: 16247815].
-
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.. Cancer immunology, immunotherapy : CII. 2005; 54(3); 254-264. [PubMed: 15372205].
-
Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.. Journal of immunology (Baltimore, Md. : 1950). 2005; 174(10); 6292-6298. [PubMed: 15879128].
-
Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.. The Prostate. 2005; 62(3); 217-223. [PubMed: 15389792].
-
Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2.. Cancer research. 2005; 65(11); 4939-4946. [PubMed: 15930316].
-
Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.. Vaccine. 2005; 23(39); 4727-4733. [PubMed: 15978705].
-
Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.. Vaccine. 2005; 23(24); 3114-3122. [PubMed: 15837210].
-
Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.. American journal of respiratory and critical care medicine. 2005; 171(10); 1168-1177. [PubMed: 15764728].
-
Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(2); 820-828. [PubMed: 16002679].
-
Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2005; 28(4); 332-342. [PubMed: 16000951].
-
Qiao H, Qian XP, Zhang HG, Tian C, Chen WF [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2005; 37(6); 565-568. [PubMed: 16378102].
-
Sugiyama H Cancer immunotherapy targeting Wilms' tumor gene WT1 product.. Expert review of vaccines. 2005; 4(4); 503-512. [PubMed: 16117707].
-
Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(11); 4168-4175. [PubMed: 15930353].
-
Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.. Experimental hematology. 2005; 33(4); 452-459. [PubMed: 15781336].
-
Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.. The Prostate. 2005; 65(4); 316-321. [PubMed: 16015596].
-
Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(9); 5799-5808. [PubMed: 16237072].
-
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(35); 9008-9021. [PubMed: 16061912].
-
Rodeberg DA, Nuss RA, Heppelmann CJ, Celis E Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.. Cancer immunology, immunotherapy : CII. 2005; 54(6); 526-534. [PubMed: 15838707].
-
Reali E, Canter D, Zeytin H, Schlom J, Greiner JW Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.. Vaccine. 2005; 23(22); 2909-2921. [PubMed: 15780740].
-
Lo HW, Day CP, Hung MC Cancer-specific gene therapy.. Advances in genetics. 2005; 54; 235-255. [PubMed: 16096014].
-
Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(8); 2879-2890. [PubMed: 15102697].
-
Frankowski DJ, Raez J, Manners I, Winnik MA, Khan SA, Spontak RJ Formation of dispersed nanostructures from poly(ferrocenyldimethylsilane-b-dimethylsiloxane) nanotubes upon exposure to supercritical carbon dioxide.. Langmuir : the ACS journal of surfaces and colloids. 2004; 20(21); 9304-9314. [PubMed: 15461522].
-
Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(3); 403-415. [PubMed: 14691123].
-
Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.. Cancer immunology, immunotherapy : CII. 2004; 53(7); 633-641. [PubMed: 14985857].
-
Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2004; 27(6); 472-477. [PubMed: 15534491].
-
Saeki A, Nakao K, Nagayama Y, Yanagi K, Matsumoto K, Hayashi T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma.. International journal of molecular medicine. 2004; 13(1); 111-116. [PubMed: 14654980].
-
Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J Autologous dendritic cell vaccines for non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(14); 2808-2815. [PubMed: 15254048].
-
Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC Progress on new vaccine strategies for the immunotherapy and prevention of cancer.. The Journal of clinical investigation. 2004; 113(11); 1515-1525. [PubMed: 15173875].
-
Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.. Cancer research. 2004; 64(17); 5934-5937. [PubMed: 15342370].
-
Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.. Vaccine. 2004; 22(11-12); 1537-1544. [PubMed: 15063579].
-
Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.. Cancer research. 2004; 64(14); 4973-4979. [PubMed: 15256471].
-
McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.. Surgery. 2004; 136(2); 437-442. [PubMed: 15300212].
-
Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(20); 6946-6955. [PubMed: 15501973].
-
Nagorsen D, Servis C, Lévy N, Provenzano M, Dudley ME, Marincola FM, Lévy F Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M.. Cancer immunology, immunotherapy : CII. 2004; 53(9); 817-824. [PubMed: 15133631].
-
Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P Gene-based vaccines and immunotherapeutics.. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101 Suppl 2(Suppl 2); 14567-14571. [PubMed: 15333750].
-
Zanetti M Protocol #0207-545: a phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma.. Human gene therapy. 2003; 14(3); 301-302. [PubMed: 12653092].
-
Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(21); 4016-4026. [PubMed: 14581425].
-
Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma.. Cancer. 2003; 98(1); 144-154. [PubMed: 12833467].
-
Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Guller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.. Human gene therapy. 2003; 14(16); 1497-1510. [PubMed: 14577912].
-
Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(11); 4247-4254. [PubMed: 14519652].
-
Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.. Journal of immunological methods. 2003; 279(1-2); 183-192. [PubMed: 12969559].
-
Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.. Cancer gene therapy. 2003; 10(11); 850-858. [PubMed: 14605671].
-
Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG L523S, an RNA-binding protein as a potential therapeutic target for lung cancer.. British journal of cancer. 2003; 88(6); 887-894. [PubMed: 12644826].
-
Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J Vaccine therapy of established tumors in the absence of autoimmunity.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(5); 1837-1849. [PubMed: 12738742].
-
Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.. Cancer research. 2003; 63(12); 3202-3210. [PubMed: 12810649].
-
Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.. Cancer research. 2003; 63(10); 2553-2560. [PubMed: 12750279].
-
Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.. The journal of gene medicine. 2003; 5(8); 690-699. [PubMed: 12898638].
-
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(8); 2973-2980. [PubMed: 12912944].
-
Marshall J Carcinoembryonic antigen-based vaccines.. Seminars in oncology. 2003; 30(3 Suppl 8); 30-36. [PubMed: 12881810].
-
Unfer RC, Hellrung D, Link CJ Jr Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy.. Cancer research. 2003; 63(5); 987-993. [PubMed: 12615713].
-
Arlen PM, Gulley JL, Tsang KY, Schlom J Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.. Expert review of vaccines. 2003; 2(4); 483-493. [PubMed: 14711334].
-
Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(9); 2782-2787. [PubMed: 12231517].
-
Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20(20); 4181-4190. [PubMed: 12377961].
-
Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.. Nature medicine. 2002; 8(12); 1369-1375. [PubMed: 12415261].
-
Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.. Human gene therapy. 2002; 13(4); 569-575. [PubMed: 11874634].
-
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.. The Journal of clinical investigation. 2002; 109(3); 409-417. [PubMed: 11828001].
-
Onaitis M, Kalady MF, Pruitt S, Tyler DS Dendritic cell gene therapy.. Surgical oncology clinics of North America. 2002; 11(3); 645-660. [PubMed: 12487060].
-
Toso JF, Lapointe R, Hwu P CD40 ligand and lipopolysaccharide enhance the in vitro generation of melanoma-reactive T-cells.. Journal of immunological methods. 2002; 259(1-2); 181-190. [PubMed: 11730853].
-
van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(5); 1019-1027. [PubMed: 12006514].
-
Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.. The Prostate. 2002; 53(2); 109-117. [PubMed: 12242725].
-
Pecher G, Häring A, Kaiser L, Thiel E Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial.. Cancer immunology, immunotherapy : CII. 2002; 51(11-12); 669-673. [PubMed: 12439613].
-
Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.. Clinical lung cancer. 2001; 3(1); 49-57; discussion 58. [PubMed: 14656392].
-
Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.. Cancer immunology, immunotherapy : CII. 2001; 50(8); 397-407. [PubMed: 11726134].
-
Rijnkels M, Rosen JM Adenovirus-Cre-mediated recombination in mammary epithelial early progenitor cells.. Journal of cell science. 2001; 114(Pt 17); 3147-3153. [PubMed: 11590241].
-
Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.. Cancer research. 2001; 61(1); 206-214. [PubMed: 11196163].
-
Holmberg LA, Sandmaier BM Theratope vaccine (STn-KLH).. Expert opinion on biological therapy. 2001; 1(5); 881-891. [PubMed: 11728222].
-
Ayyoub M, Migliaccio M, Guillaume P, Liénard D, Cerottini JC, Romero P, Lévy F, Speiser DE, Valmori D Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.. European journal of immunology. 2001; 31(9); 2642-2651. [PubMed: 11536162].
-
Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(23); 13255-13260. [PubMed: 11687624].
-
Schütz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, Heberer M, Zajac P Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.. Cancer gene therapy. 2001; 8(9); 655-661. [PubMed: 11593334].
-
Cohen EE, Rudin CM ONYX-015. Onyx Pharmaceuticals.. Current opinion in investigational drugs (London, England : 2000). 2001; 2(12); 1770-1775. [PubMed: 11892945].
-
Motta I, André F, Lim A, Tartaglia J, Cox WI, Zitvogel L, Angevin E, Kourilsky P Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells.. Journal of immunology (Baltimore, Md. : 1950). 2001; 167(3); 1795-1802. [PubMed: 11466405].
-
Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector.. Annals of the New York Academy of Sciences. 2000; 910; 237-252. [PubMed: 10911917].
-
Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.. Vaccine. 2000; 19(4-5); 530-537. [PubMed: 11027818].
-
Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000; 6(5); 1632-1638. [PubMed: 10815880].
-
Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.. Human gene therapy. 2000; 11(17); 2377-2387. [PubMed: 11096442].
-
Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, Acres B Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2000; 23(5); 570-580. [PubMed: 11001550].
-
Lees CJ, Apostolopoulos V, Acres B, Ramshaw I, Ramsay A, Ong CS, McKenzie IF Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.. Vaccine. 2000; 19(2-3); 158-162. [PubMed: 10930667].
-
Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G, Livingston P Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.. British journal of cancer. 1999; 79(11-12); 1806-1812. [PubMed: 10206297].
-
Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J A triad of costimulatory molecules synergize to amplify T-cell activation.. Cancer research. 1999; 59(22); 5800-5807. [PubMed: 10582702].
-
Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.. Cancer research. 1999; 59(2); 301-306. [PubMed: 9927036].
-
Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.. The Journal of experimental medicine. 1999; 190(11); 1669-1678. [PubMed: 10587357].
-
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.. Nature medicine. 1998; 4(3); 321-327. [PubMed: 9500606].
-
Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(6); 3186-3194. [PubMed: 9743387].
-
Ragupathi G, Koganty RR, Qiu D, Lloyd KO, Livingston PO A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.. Glycoconjugate journal. 1998; 15(3); 217-221. [PubMed: 9579798].
-
Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide.. International journal of cancer. 1998; 76(6); 817-823. [PubMed: 9626347].
-
Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.. The Journal of clinical investigation. 1997; 100(11); 2783-2792. [PubMed: 9389743].
-
Grossmann ME, Brown MP, Brenner MK Antitumor responses induced by transgenic expression of CD40 ligand.. Human gene therapy. 1997; 8(16); 1935-1943. [PubMed: 9382959].
-
Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.. Journal of immunotherapy (Hagerstown, Md. : 1997). 1997; 20(1); 38-47. [PubMed: 9101412].
-
Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.. Clinical immunology and immunopathology. 1997; 85(3); 265-272. [PubMed: 9400626].
-
Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(10); 4781-4786. [PubMed: 8643480].
-
Date Y, Kimura A, Kato H, Sasazuki T DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese.. Tissue antigens. 1996; 47(2); 93-101. [PubMed: 8851721].
-
Qin H, Chatterjee SK Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF.. Human gene therapy. 1996; 7(15); 1853-1860. [PubMed: 8894677].
-
Yang G, Hellström KE, Hellström I, Chen L Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.. Journal of immunology (Baltimore, Md. : 1950). 1995; 154(6); 2794-2800. [PubMed: 7533183].
-
Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, Marrogi A The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study.. Human gene therapy. 1995; 6(7); 927-939. [PubMed: 7578411].
-
Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, González-García M, Doedens M, Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Núñez G A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells.. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92(24); 11024-11028. [PubMed: 7479929].
-
Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.. Journal of the National Cancer Institute. 1995; 87(13); 982-990. [PubMed: 7629885].
-
Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994; 12(2); 402-411. [PubMed: 8113848].
-
Jiménez-Cervantes C, Solano F, Kobayashi T, Urabe K, Hearing VJ, Lozano JA, García-Borrón JC A new enzymatic function in the melanogenic pathway. The 5,6-dihydroxyindole-2-carboxylic acid oxidase activity of tyrosinase-related protein-1 (TRP1).. The Journal of biological chemistry. 1994; 269(27); 17993-18000. [PubMed: 8027058].
-
Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma.. Cancer research. 1993; 53(21); 5108-5112. [PubMed: 8221646].
-
Longenecker BM, Reddish M, Koganty R, MacLean GD Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.. Annals of the New York Academy of Sciences. 1993; 690; 276-291. [PubMed: 7690215].
-
Ding L, Lalani EN, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PY, Taylor-Papadimitriou J Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.. Cancer immunology, immunotherapy : CII. 1993; 36(1); 9-17. [PubMed: 8422670].
-
Wallack MK, Bash JA, McNally KR, Leftheriotis E Serological evaluation of melanoma patients in a phase I/II trial of vaccinia melanoma oncolysate (VMO) immunotherapy.. Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc. 1987; 1; 351-359. [PubMed: 3155379].
-
Sirisinha S, Eisen HN Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.. Proceedings of the National Academy of Sciences of the United States of America. 1971; 68(12); 3130-3135. [PubMed: 4108872].
-
FDA: Gardasil information [http://www.fda.gov/Cber/products/gardasil.htm]
-
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors [https://clinicaltrials.gov/ct2/show/NCT03544723]
-
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer [https://clinicaltrials.gov/ct2/show/NCT02636582]
-
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients [https://clinicaltrials.gov/ct2/show/NCT05479045]
-
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine [https://clinicaltrials.gov/ct2/show/NCT00199849]
-
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer [https://clinicaltrials.gov/ct2/show/NCT00616291]
-
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer [https://clinicaltrials.gov/ct2/show/NCT00199836]
-
p53 Vaccine for Ovarian Cancer [https://clinicaltrials.gov/ct2/show/NCT00001827]
-
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (PERFORMANCE) [https://clinicaltrials.gov/ct2/show/NCT02864368]
-
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS) [https://clinicaltrials.gov/ct2/show/NCT02562755]
-
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (Cornerstone001) [https://clinicaltrials.gov/ct2/show/NCT05163223]
-
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer [https://clinicaltrials.gov/ct2/show/NCT00345293]
-
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE) [https://clinicaltrials.gov/ct2/show/NCT02111577]
-
Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA) [https://clinicaltrials.gov/ct2/show/NCT02058680]
-
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer [https://clinicaltrials.gov/ct2/show/NCT00019591]
-
Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma [https://clinicaltrials.gov/ct2/show/NCT00924092]
-
Safety and Efficacy Study Using Rexin-G for Breast Cancer [https://clinicaltrials.gov/ct2/show/NCT00505271]
-
Maveropepimut-S (Code C97951) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97951]
-
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (TRT-001) [https://clinicaltrials.gov/ct2/show/NCT02960594]
-
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 [https://clinicaltrials.gov/ct2/show/NCT02362464]
-
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH [https://clinicaltrials.gov/ct2/show/NCT02855892]
-
Novel Adjuvants for Peptide-Based Melanoma Vaccines [https://clinicaltrials.gov/ct2/show/NCT00028431]
-
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer [https://clinicaltrials.gov/ct2/show/NCT00681577]
-
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer [https://clinicaltrials.gov/ct2/show/NCT00632333]
-
Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) [https://clinicaltrials.gov/ct2/show/NCT00655785]
-
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma [https://clinicaltrials.gov/ct2/show/NCT01718899]
-
PD-L1/IDO Peptide Vaccine IO102-103 [https://ncithesaurus.nci.nih.gov/ncitbrowser/pages/home.jsf]
-
Colorectal Cancer Peptide Vaccine PolyPEPI1018 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278]
-
Polyvalent Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633]
-
Prodencel [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174]
-
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127910]
-
Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C156067]
-
mRNA-derived KRAS-targeted Vaccine V941 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186]
-
Melanoma TRP2 CTL Epitope Vaccine SCIB1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380]
-
Oral Cancer Vaccine V3-OVA [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540]
-
RAS Peptide Cancer Vaccine TG01 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465]
-
Transgenic Lymphocyte Immunization Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720]
-
Adenoviral Brachyury Vaccine ETBX-051 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034]
-
Adenoviral MUC1 Vaccine ETBX-061 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035]
-
Total Tumor RNA-loaded Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913]
-
Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522]
-
Dendritic Cell Tumor Cell Lysate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1988]
-
4-Peptide Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722]
-
GM.CD40L Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391]
-
Pentavalent KLH Conjugate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034]
-
Autologous Vaccine-enhanced Ex Vivo Activated Cancer Neoantigens-specific T-cells TVI-Brain-1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632]
-
Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858]
-
Autologous AML/Dendritic Cell Fusion Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148214]
-
Dendritic Cell Tumor Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987]
-
Neoantigen-loaded Autologous Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422]
-
ESR1 Peptides/GM-CSF/Montanide ISA Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590]
-
Autologous Follicular Lymphoma-Derived Idiotype Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036]
-
GM-K562 Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190]
-
HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392]
-
Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592]
-
MAGE-A1, Her-2/neu, FBP Peptides Cancer Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775]
-
Autologous mDC3 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250]
-
Mixed Bacteria Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063]
-
Autologous CMV-pp65-LAMP mRNA Loaded Monocyte Vaccine MT-201-GBM [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670]
-
MUC1 Peptide-Poly-ICLC Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417]
-
Multi-epitope HER2 Peptide Vaccine TPIV100 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525]
-
Multi-epitope Melanoma Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695]
-
Prime Cancer Vaccine MVA-BN-CV301 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059]
-
MVF-HER-2(628-647)-CRL 1005 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637]
-
Autologous Dendritic Cell/Myeloma Fusion Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480]
-
mRNA-based Personalized Cancer Vaccine NCI-4650 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239]
-
Personalized Peptide Cancer Vaccine NEO-PV-01 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935]
-
Neoantigen Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508]
-
NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127125]
-
Personalized Synthetic Long Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471]
-
Oral Therapeutic Vaccine V3-X [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144]
-
NCIT_C2763 [https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2763]
-
[https://clinicaltrials.gov/ct2/show/NCT00028496?term=Recombinant+Fowlpox-CEA%286D%29%2FTRICOM+Vaccine&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT00726739]
-
[https://clinicaltrials.gov/show/NCT00071942/]
-
[https://clinicaltrials.gov/ct2/show/NCT02654587]
-
[https://clinicaltrials.gov/show/NCT02323230/]
-
[https://clinicaltrials.gov/show/NCT00972309/]
-
[https://clinicaltrials.gov/ct2/show/NCT00109655?term=CG0070&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT00411749?term=V501&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT00030823?term=Globo-H-GM2-Lewis-y-MUC1-32%28aa%29-sTn%28c%29-TF%28c%29-Tn%28c%29-KLH+Conjugate+Vaccine&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT00100971]
-
[https://clinicaltrials.gov/ct2/show/NCT01744171]
-
[https://clinicaltrials.gov/show/NCT00121173]
-
[https://clinicaltrials.gov/ct2/show/NCT00006216]
-
[https://clinicaltrials.gov/show/NCT01322802]
-
[https://clinicaltrials.gov/show/NCT02334865/]
-
[https://clinicaltrials.gov/show/NCT01334060]
-
[https://clinicaltrials.gov/ct2/show/NCT01498328]
-
[https://clinicaltrials.gov/ct2/show/NCT00798629?term=gp100+Adenovirus+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT00423254/]
-
[https://clinicaltrials.gov/ct2/show/NCT00015977]
-
[https://clinicaltrials.gov/ct2/show/NCT01690377]
-
[https://clinicaltrials.gov/ct2/show/NCT02460367]
-
[https://clinicaltrials.gov/ct2/show/NCT00006106?term=ONYX-015&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT01307618?term=NA17.A2&rank=2]
-
[https://clinicaltrials.gov/show/NCT00859729]
-
[https://clinicaltrials.gov/ct2/show/NCT02170389]
-
[https://clinicaltrials.gov/show/NCT00574977]
-
[https://clinicaltrials.gov/show/NCT00019006/]
-
[https://clinicaltrials.gov/ct2/show/NCT02773849?term=Instiladrin&rank=1]
-
[https://clinicaltrials.gov/show/NCT00304096/]
-
[https://clinicaltrials.gov/show/NCT00109811/]
-
[https://clinicaltrials.gov/show/NCT01022346/]
-
[https://clinicaltrials.gov/show/NCT00900809/]
-
[https://clinicaltrials.gov/show/NCT00033228]
-
[https://clinicaltrials.gov/ct2/show/NCT02033616]
-
[https://clinicaltrials.gov/show/NCT00069940/]
-
[https://clinicaltrials.gov/show/NCT00019383/]
-
[https://clinicaltrials.gov/show/NCT01621542/]
-
[https://clinicaltrials.gov/show/NCT00694551/]
-
[https://clinicaltrials.gov/show/NCT00005039/]
-
[https://clinicaltrials.gov/show/NCT00988559]
-
[https://clinicaltrials.gov/show/NCT02499835]
-
[https://clinicaltrials.gov/ct2/show/NCT00091273]
-
[https://clinicaltrials.gov/show/NCT00081848/]
-
[https://clinicaltrials.gov/show/NCT01220128/]
-
[https://clinicaltrials.gov/ct2/show/NCT00054535?term=Recombinant+Fowlpox-Tyrosinase+Vaccine&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT00004211]
-
[https://clinicaltrials.gov/show/NCT00019734/]
-
[https://clinicaltrials.gov/ct2/show/NCT00062907?term=Recombinant+Adenovirus+L523S+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT00002817/]
-
[https://clinicaltrials.gov/show/NCT00112957/]
-
[https://clinicaltrials.gov/ct2/show/NCT02015416]
-
[https://clinicaltrials.gov/ct2/show/NCT00389610]
-
[https://clinicaltrials.gov/ct2/show/NCT00066404?term=Recombinant+Adenovirus-hIFN-beta&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT00313508]
-
[https://clinicaltrials.gov/ct2/show/NCT02410733]
-
[https://clinicaltrials.gov/show/NCT00140738/]
-
[https://clinicaltrials.gov/show/NCT00023647]
-
[https://clinicaltrials.gov/ct2/show/NCT02427581]
-
[https://clinicaltrials.gov/show/NCT00493545/]
-
[https://clinicaltrials.gov/show/NCT00471133]
-
[https://clinicaltrials.gov/ct2/show/NCT00978913]
-
[https://clinicaltrials.gov/show/NCT00062907]
-
[https://clinicaltrials.gov/ct2/show/NCT01334047]
-
[https://clinicaltrials.gov/ct2/show/NCT00844506?term=P53-Synthetic+Long+Peptides+Vaccine&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT01253837]
-
[https://clinicaltrials.gov/show/NCT01784913/]
-
[https://clinicaltrials.gov/ct2/show/NCT00612222?term=ALVAC-MART-1+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT00523159/]
-
[https://clinicaltrials.gov/ct2/show/NCT02293850?term=OBP-301&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT01598454]
-
[https://clinicaltrials.gov/ct2/show/NCT01171729]
-
[https://clinicaltrials.gov/ct2/show/NCT00005039?term=Recombinant+Fowlpox-Prostate+Specific+Antigen+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT01961882/]
-
[https://clinicaltrials.gov/show/NCT00285259]
-
[https://clinicaltrials.gov/show/NCT02718443]
-
[https://clinicaltrials.gov/show/NCT02149225/]
-
[https://clinicaltrials.gov/ct2/show/NCT00001564]
-
[https://clinicaltrials.gov/ct2/show/NCT00001561]
-
[https://clinicaltrials.gov/show/NCT00624182/]
-
[https://clinicaltrials.gov/ct2/show/NCT00108732?term=Fowlpox-PSA-TRICOM+Vaccine&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT01308294?term=Melan-A%2FMAGE-3.DP4+Peptide+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT02772562/]
-
[https://clinicaltrials.gov/ct2/show/NCT00072137?term=Recombinant+Fowlpox+GM-CSF+Vaccine+Adjuvant&rank=1]
-
[https://clinicaltrials.gov/show/NCT02514213]
-
[https://clinicaltrials.gov/ct2/show/NCT00002960?term=Recombinant+Adenovirus+p53+SCH+58500&rank=1]
-
[https://clinicaltrials.gov/show/NCT00022438/]
-
[https://clinicaltrials.gov/ct2/show/NCT00626015?term=PEP-3-KLH&rank=1]
-
[https://clinicaltrials.gov/show/NCT00004918/]
-
[https://clinicaltrials.gov/show/NCT00001703/]
-
[https://clinicaltrials.gov/show/NCT00725283/]
-
[https://clinicaltrials.gov/ct2/show/NCT01095848]
-
[https://clinicaltrials.gov/show/NCT01842139/]
-
[https://clinicaltrials.gov/show/NCT02649439/]
-
[https://clinicaltrials.gov/ct2/show/NCT02439450]
-
[https://clinicaltrials.gov/ct2/show/NCT00499577?term=hTERT+I540%2FR572Y%2FD988Y+Multipeptide+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT00227474/]
-
[https://clinicaltrials.gov/ct2/show/NCT01216436]
-
[https://clinicaltrials.gov/show/NCT00639925/]
-
[https://clinicaltrials.gov/ct2/show/NCT00080353?term=Recombinant+Fowlpox-gp100p209&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT02107950]
-
[https://clinicaltrials.gov/ct2/show/NCT00003638]
-
[https://clinicaltrials.gov/ct2/show/NCT00030693?term=Recombinant+Fowlpox-B7.1+Vaccine&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT02795988]
-
[https://clinicaltrials.gov/ct2/show/NCT00514072]
-
[https://clinicaltrials.gov/ct2/show/NCT00004156?term=MUC1-KLH+Vaccine%2FQS21&rank=1]
-
[https://clinicaltrials.gov/ct2/show/NCT02159950]
-
[https://clinicaltrials.gov/ct2/show/NCT00049218]
-
[https://clinicaltrials.gov/show/NCT00516685/]
-
[https://clinicaltrials.gov/ct2/show/NCT00450619?term=TRICOM+Vaccine&rank=1]
-
[https://clinicaltrials.gov/show/NCT00116597/]
-
[https://clinicaltrials.gov/show/NCT02128126/]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121777]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91719]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2640]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2761]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2648]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114755]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2798]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95211]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95212]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53290]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29982]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116740]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90540]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88279]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29945]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121570]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C124054]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C112206]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28682]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61077]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61076]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78861]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28330]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71533]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48412]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48414]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90572]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104419]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90570]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90571]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79799]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2501]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120129]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74000]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70985]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85462]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85463]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2464]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2465]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85466]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85464]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113794]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96042]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91377]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91379]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91378]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38123]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38122]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38121]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61082]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113647]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61087]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77878]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28860]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77874]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97666]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97665]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104738]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74090]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61327]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2214]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2606]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104734]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104737]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C92573]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61495]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88326]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114293]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29187]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82352]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2781]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91710]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2732]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78448]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48816]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71758]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67082]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49290]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67089]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111991]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121640]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111998]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121947]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99228]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29334]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37448]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29338]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82675]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74070]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113807]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C118851]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C118852]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C68839]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2423]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2426]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2424]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38117]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2428]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116321]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2816]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2815]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77910]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85452]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111900]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64773]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78830]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C125692]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26450]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85451]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74057]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73438]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28780]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120118]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2497]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49087]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113296]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2492]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49082]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116848]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114380]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77900]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77907]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79832]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74015]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2675]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2674]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2776]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2774]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2775]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70968]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71741]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95751]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95759]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64846]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29476]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71761]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2807]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84844]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88289]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90569]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123923]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78862]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64635]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116879]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29558]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116777]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48368]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2512]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2510]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119617]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28784]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74016]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62452]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85479]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29068]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85470]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113786]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123918]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123919]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61098]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113653]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113651]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113432]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74066]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62527]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48418]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82361]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48419]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82416]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29786]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2680]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2686]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84854]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96737]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96738]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78865]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C30000]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77895]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73999]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2339]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67098]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73995]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77863]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28550]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26681]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26680]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102541]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1690]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95727]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2783]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66985]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2023]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106242]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C98287]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C51978]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116332]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116331]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28503]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74064]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70674]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90592]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84755]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64785]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26446]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26445]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C69076]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26449]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74023]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2241]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85445]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2485]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62768]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62767]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116847]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29337]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2805]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2806]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82420]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79842]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1830]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2809]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107243]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49177]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2742]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2741]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2740]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29785]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103830]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2666]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2667]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99378]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78489]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78487]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29918]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114496]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91076]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91077]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121856]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29564]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2341]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29409]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29560]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29563]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29402]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2063]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2060]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29401]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1648]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99116]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28549]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115105]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82654]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115106]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1985]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1986]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1980]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1982]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1983]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97265]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85456]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90558]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29317]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90555]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116868]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48371]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120039]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122396]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53410]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2445]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96739]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2830]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29566]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70644]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C105806]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97344]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1979]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1978]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101892]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101891]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119759]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1977]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2620]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77909]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114295]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123283]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C126797]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2236]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2235]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78193]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82371]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82407]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2403]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111037]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107159]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2657]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73998]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2718]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2650]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2710]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61442]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77867]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114990]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102787]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C68999]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78819]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106257]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99129]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48395]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103192]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102978]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94217]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94216]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29088]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94210]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94218]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74036]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62479]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104743]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99902]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116067]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2474]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49064]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2471]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49063]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2473]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49023]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C118364]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119664]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123930]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120183]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29316]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2754]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102751]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102753]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103823]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74087]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74088]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74089]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28776]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28775]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29192]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95024]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102982]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1159]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29908]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95771]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121848]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2057]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2055]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91707]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119614]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26645]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29555]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29559]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113174]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49289]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116888]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C124652]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48465]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116880]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115976]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61146]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37515]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90542]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38715]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119616]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95705]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29910]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38708]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2430]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85450]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115101]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2436]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2439]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2438]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2824]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99903]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2822]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2821]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48640]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38681]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71723]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114289]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104747]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2384]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114285]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48632]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48638]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48639]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74042]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2540]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82388]
-
[https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91714]
NOTE: Go to Litesearch, Vaxpresso and Vaxmesh for advanced literature search.
|
